ITEM 1.01. ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

The Transaction Agreement

On January 9, 2022, R1 RCM Inc. (the "Company"), Project Roadrunner Parent Inc., a wholly owned subsidiary of the Company ("NewR1"), Project Roadrunner Merger Sub Inc., a wholly owned subsidiary of NewR1 ("R1 Merger Sub"), Coyco 1, L.P., a Delaware limited partnership ("Coyco 1") and Coyco 2, L.P., a Delaware limited partnership ("Coyco 2" and, together with Coyco 1, the "Sellers") entered into a Transaction Agreement and Plan of Merger (the "Transaction Agreement"), pursuant to which the Company has agreed to purchase the business of the subsidiaries of the Sellers, which includes Cloudmed, a leader in Revenue Intelligence™ solutions for healthcare providers (collectively, the "Cloudmed entities"), through (i) a merger of R1 Merger Sub with and into the Company with the Company as the surviving entity, which will result in the Company becoming a wholly owned subsidiary of NewR1 (the "Holding Company Reorganization") and (ii) the Sellers contributing 100% of the equity of a blocker parent corporation of the Cloudmed entities in exchange for shares of common stock, par value $0.01 per share of NewR1 ("NewR1 Common Stock") equal to approximately 30% of the fully diluted shares of R1 Common Stock as of the date of the Transaction Agreement on a pro forma basis after giving effect to the Transaction (as defined below), subject to certain adjustments set forth in the Transaction Agreement (the "Acquisition", and together with the Holding Company Reorganization, the "Transactions").

The consummation of the Transactions is subject to certain conditions, including, among other things (a) the expiration or termination of all waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder ("HSR Approval"), (b) the effectiveness of the Registration Statement (as defined below) relating to the Holding Company Reorganization, (c) approval by shareholders of the Company of the issuance of NewR1 Common Stock to the Sellers (the "Issuance"), (d) approval for listing on The Nasdaq Stock Market LLC ("Nasdaq") of the shares of NewR1 Common Stock, subject to official notice of issuance, (e) approval pursuant to the EU Merger Regulation, Council Regulation (EC) No 139/2004 and (f) other customary closing conditions. The Transaction Agreement may be terminated, among other things, (i) by mutual consent of the Company and the Sellers, (ii) by the Company or the Sellers upon a breach of certain of the representation and warranties in the Transaction Agreement by the other which has not been cured, (iii) if the shareholders of the Company do not approve the issuance of NewR1 Common Stock to the Sellers, (iv) if an order is issued by an applicable governmental authority permanently enjoining the consummation of the Transactions or (v) if the closing of the transaction has not occurred on or prior to July 31, 2022. The Transaction Agreement contains certain representations and warranties and covenants as specified therein, including such provisions as are customary for a transaction of this nature.

The foregoing description of the transaction and the Transaction Agreement does not purport to be complete and is qualified in its entirety by reference to the Transaction Agreement, which will be filed by amendment on Form 8-K/A to this Current Report within four business days of the date hereof as Exhibit 2.1.

Holding Company Reorganization

Pursuant to the Transaction Agreement, immediately prior to the completion of the Acquisition, the Company will implement the Holding Company Reorganization, which will result in NewR1 owning all of the capital stock of the Company. NewR1 will initially be a direct, wholly owned subsidiary of the Company. Pursuant to the Holding Company Reorganization, R1 Merger Sub, a newly formed entity and a direct, wholly owned subsidiary of NewR1 and an indirect, wholly owned subsidiary of the Company, will merge with and into the Company, with the Company surviving as a direct, wholly owned subsidiary of NewR1. Each share of the Company's common stock, par value $0.01 per share ("Company Common Stock"), issued and outstanding immediately prior to the Holding Company Reorganization will automatically be exchanged into an equivalent corresponding share of NewR1 Common Stock, having the same designations, rights, powers and preferences and the qualifications, limitations and restrictions as the corresponding share of Company Common Stock being converted. Accordingly, upon consummation of the Holding Company Reorganization, the Company's current stockholders will become stockholders of NewR1.

--------------------------------------------------------------------------------

The Holding Company Reorganization will be conducted pursuant to Section 251(g) of the General Corporation Law of the State of Delaware, which provides for the formation of a holding company through a merger without a vote of the stockholders of the constituent corporations. Effective upon the consummation of the Holding Company Reorganization, NewR1 will adopt an amended and restated certificate of incorporation and amended and restated bylaws that are identical to those of the Company immediately prior to the consummation of the Holding Company Reorganization, except for the change of the name of the corporation as permitted by Section 251(g).

Furthermore, the conversion will occur automatically without an exchange of stock certificates. Stock certificates previously representing shares of Company Common Stock will represent the same number of shares of NewR1 Common Stock after the Holding Company Reorganization. Each person entered as the owner in a book entry that, immediately prior to the Holding Company Reorganization, . . .

ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

The information in Item 2.02 of this Current Report on Form 8-K of the Company is intended to furnish certain estimated financial and operating results of the Company as of and for the fiscal year ended December 31, 2021 as set forth in Exhibit 99.2 to this Current Report on Form 8-K.

The estimated financial and operating results as of and for the Company's fiscal year ended December 31, 2021 included in Exhibit 99.2 hereto are preliminary, unaudited and subject to completion, reflect management's current views, and may change as a result of management's review of results and other factors, including a wide variety of significant business, economic and competitive risks and uncertainties. Such preliminary results are subject to the finalization of year-end financial and accounting procedures (which have yet to be performed) and should not be viewed as a substitute for full audited annual financial statements prepared in accordance with U.S. generally accepted accounting principles. The actual results may be materially different from the estimated results. See the factors discussed under the caption "Risk Factors" in Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.2 hereto, is being "furnished" to comply with Item 2.02 of Form 8-K and shall not be deemed "filed" by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in any such filing.

ITEM 7.01. REGULATION FD DISCLOSURE.

On January 10, 2022, the Company and the Cloudmed entities issued a joint press release (the "Press Release") announcing the execution of the Transaction Agreement. The Press Release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Attached as Exhibit 99.2 and incorporated by reference herein is an investor presentation dated January 10, 2022, for use by the Company in meetings with certain of its shareholders as well as other persons with respect to the Transactions, as described in this Current Report on Form 8-K.

The information in this Item 7.01, including Exhibit 99.1 and Exhibit 99.2 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filings. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information of the information contained in this Item 7.01, including Exhibit 99.1 and Exhibit 99.2.




ITEM 8.01. OTHER EVENTS.

Debt Commitment Letters

Concurrently with the signing of the Transaction Agreement, the Company entered into a debt commitment letter, dated as of January 9, 2022 (the "Commitment Letter"), with JPMorgan Chase Bank, N.A. and Barclays Bank PLC as set forth therein, for a $1,040 million incremental first lien term loan B facility (the "Incremental Term Loan"). The Commitment Letter and the commitments contemplated thereby will terminate on August 5, 2022

--------------------------------------------------------------------------------

(five (5) business days after the termination date with respect to the Agreement). The proceeds of the Incremental Term Loan will be used, together with the Company's cash on hand, to finance the Transactions (including related fees and expense). The Incremental Term Loan will have terms generally consistent with those of the Company's existing term loans (the "Initial Term Loans") under the Credit Agreement, dated as of July 1, 2021 (as amended, restated, amended and restated, supplemented or otherwise modified, the "Credit Agreement"), by and among the Company, certain of its subsidiaries, Bank of America, N.A., as administrative agent, and the lenders named therein, including with respect to customary interest, maturity, amortization and prepayments for an incremental term loan B facility, as set forth in the Commitment Letter.

The commitments set forth in the Commitment Letter are subject to customary conditions contained in the Commitment Letter, including the execution of definitive documentation and the consummation of the Transactions. The representations and warranties, affirmative and negative covenants, indemnity obligations and events of default set forth in the Credit Agreement will apply to the Incremental Term Loan. The Company will pay certain customary fees in connection with the Incremental Term Loan.

In addition, on January 9, 2022, the Company entered into a debt financing engagement letter with JPMorgan Chase Bank, N.A. and Barclays Bank PLC to embark on a best efforts process to obtain, (i) a senior secured incremental revolving credit facility in an aggregate principal amount of up to $100,000,000 (the "Incremental Revolving Credit Facility"), (ii) senior secured incremental term A loan facility in an expected principal amount of $500,000,000 (the "Incremental Term Loan A Facility"), and (iii) senior secured incremental delayed-draw term B loan facility in an aggregate principal amount of up to $500,000,000 (the "Incremental Delayed-Draw Term Loan B Facility", and together with the Incremental Revolving Credit Facility and the Incremental Term Loan A Facility, the "Facilities"), the proceeds of which to be applied to, among other things, (x) to fund the Transaction and to pay the fees, premiums, expenses and other transaction costs incurred in connection therewith, and (y) with respect to the Incremental Revolving Loans, for working capital, general corporate purposes, and any other purposes not prohibited by the Credit Agreement. There can be no assurances that such best efforts financing of the Facilities will be completed. If such best efforts financing is completed as contemplated, the Company will not incur the full amount of the Incremental Term Loans described above.

Additional Information and Where to Find It

This Current Report on Form 8-K relates to a proposed transaction between the Company and the Cloudmed entities. This Current Report on Form 8-K does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The Company intends to file a registration statement on Form S-4 with the U.S. Securities and Exchange Commission (the "SEC"), which will include a document that serves as a prospectus and proxy statement of the Company, referred to as a proxy statement / prospectus. A proxy statement / prospectus will be sent to all shareholders of the Company. The Company also will file other documents regarding the proposed transaction with the SEC. Before making any voting decision, investors and security holders of the Company are urged to read the registration statement, the proxy statement / prospectus and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed transaction.

Investors and security holders will be able to obtain free copies of the registration statement, the proxy statement / prospectus and all other relevant documents filed or that will be filed with the SEC by the Company through the website maintained by the SEC at www.sec.gov.

The documents filed by the Company with the SEC also may be obtained free of charge at the Company's website at https://r1rcm.com/ or upon written request to 434 W. Ascension Way, 6th Floor, Murray, Utah 84123.

Participants in Solicitation

The Company and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the Company's shareholders in connection with the proposed transaction. A list of the names of such

--------------------------------------------------------------------------------

directors and executive officers and information regarding their interests in the Transactions will be contained in the proxy statement / prospectus when available. You may obtain free copies of these documents as described in the preceding paragraph.

Forward-Looking Statements

This Current Report on Form 8-K includes information that may constitute "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events and relationships, plans, future growth and future performance, including, but not limited to, statements about the expected timing, completion and effects of the proposed transaction, our strategic initiatives, our capital plans, our costs, our ability to successfully implement new technologies, our future financial and operational performance, and our liquidity. These statements are often identified by the use of words such as "anticipate," "believe," "estimate," "expect," "intend," "designed," "may," "plan," "predict," "project," "target," "contemplate," "would," "seek," "see" and similar expressions or variations or negatives of these words, although not all forward-looking statements contain these identifying words. These statements are based on various assumptions, whether or not identified in this presentation, and on the current expectations of the Company's and Cloudmed's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, assurance, prediction or definitive statement of fact or probability. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks, and changes in circumstances, including but not limited to risk and uncertainties related to: (i) the ability of the parties to consummate the proposed transaction in a timely manner or at all; (ii) satisfaction of the conditions precedent to the consummation of the proposed transaction, including the receipt of required regulatory and shareholder approvals; (iii) the Company's ability to timely and successfully achieve the anticipated benefits and potential synergies of the proposed transaction, and (iv) the impact of health epidemics, including the COVID-19 pandemic, on our business and any actions that we may take in response thereto. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the heading "Risk Factors" in our annual report on Form 10-K for the year ended December 31, 2020, our quarterly reports on Form 10-Q, the registration statement on Form S-4 and the proxy statement included therein that NewR1 intends to file relating to the transactions described herein and any other periodic reports that we file with the SEC. The foregoing list of factors is not exhaustive. All forward-looking statements included herein are expressly qualified in their entirety by these cautionary statements as of the date hereof and involve many risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in our forward-looking statements. Subsequent events and developments, including actual results or changes in our assumptions, may cause our views to change. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law. You are cautioned not to place undue reliance on such forward-looking statements.

This Current Report on Form 8-K shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Transactions.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.





(d) Exhibits




2.1^     Transaction Agreement and Plan of Merger, dated as of January 9, 2022
         among the Company, NewR1, R1 Merger Sub and the Sellers

4.1^     Form of Second Amended and Restated Registration Rights Agreement between
         the Company, NewR1, TCP-ASC, IHC, LifePoint and the Sellers

4.2^     Form of Amended and Restated Investor Rights Agreement between the
         Company, NewR1 and TCP-ASC

4.3^     Form of Investor Rights Agreement between NewR1 and the Sellers

10.1^    Voting Agreement, dated as of January 9, 2022, between the Company,
         Revint and TCP-ASC

99.1*      Press release dated January 10, 2022

99.2*      Investor presentation dated January 10, 2022

104      Cover Page Interactive Data File - the cover page iXBRL tags are embedded
         within the Inline XBRL document




* -Filed herewith


^ -To be filed by amendment


--------------------------------------------------------------------------------

© Edgar Online, source Glimpses